Charles Zhu
Stock Analyst at Guggenheim
(2.69)
# 1,907
Out of 5,124 analysts
20
Total ratings
52.17%
Success rate
22.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $8.86 | +35.44% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $11.86 | +85.50% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $2.60 | - | 1 | Dec 13, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.61 | +645.34% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $100.59 | -44.33% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.33 | +312.76% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $35.52 | -26.80% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $34.57 | -7.43% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $26.33 | -46.83% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $8.86
Upside: +35.44%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $11.86
Upside: +85.50%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.60
Upside: -
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $100.59
Upside: -44.33%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.33
Upside: +312.76%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $35.52
Upside: -26.80%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $34.57
Upside: -7.43%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $26.33
Upside: -46.83%